

USE OF ASPIRIN IN PRIMARY PREVENTION FOR CARDIOVASCULAR EVENTS

Primary prevention in non-diabetics	Primary prevention in diabetics	Secondary prevention (diabetics and non-diabetics)
Aspirin not recommended for primary prevention even in those at highest risk because the absolute benefits are very small (NNT 1666 and NNH 3333) Benefits and harms similar for men and women. Benefit did not change significantly with age.	Evidence suggests aspirin should not be started for primary prevention of CVD even if high risk groups such as diabetes [POPADAD trial]	Recommend to all (NNT 66) unless contraindication